News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
60,331 Results
Type
Article (852)
Company Profile (6)
Press Release (59473)
Section
Business (20529)
Career Advice (28)
Deals (5396)
Drug Delivery (1)
Drug Development (5503)
Employer Resources (7)
FDA (1118)
Job Trends (1376)
News (32237)
Policy (2328)
Tag
Academia (160)
Accelerated approval (1)
Allergies (3)
Alliances (3081)
ALS (15)
Alzheimer's disease (162)
Antibody-drug conjugate (ADC) (24)
Approvals (1167)
Artificial intelligence (42)
Autoimmune disease (6)
Automation (5)
Bankruptcy (23)
Best Places to Work (1302)
BIOSECURE Act (1)
Biosimilars (5)
Biotechnology (5)
Bladder cancer (11)
Brain cancer (9)
Breast cancer (46)
Cancer (435)
Cardiovascular disease (45)
Career advice (20)
CAR-T (13)
CDC (1)
Cell therapy (40)
Cervical cancer (3)
Clinical research (5028)
Collaboration (116)
Compensation (93)
Complete response letters (2)
COVID-19 (154)
CRISPR (6)
C-suite (61)
Data (737)
Depression (24)
Diabetes (41)
Diagnostics (872)
Digital health (5)
Diversity, equity & inclusion (3)
Drug discovery (11)
Drug pricing (1)
Duchenne muscular dystrophy (25)
Earnings (15039)
Employer branding (1)
Employer resources (5)
Events (7226)
Executive appointments (72)
FDA (1522)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (125)
Gene editing (14)
Gene therapy (28)
GLP-1 (59)
Government (218)
Guidances (138)
Healthcare (1912)
HIV (2)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (5)
Immuno-oncology (2)
Indications (13)
Infectious disease (184)
Inflammatory bowel disease (5)
Influenza (23)
Intellectual property (42)
Interviews (11)
IPO (3465)
Job creations (108)
Job search strategy (19)
Labor market (1)
Layoffs (15)
Legal (643)
Liver cancer (9)
Longevity (2)
Lung cancer (34)
Lymphoma (33)
Machine learning (5)
Management (1)
Manufacturing (45)
MASH (9)
Medical device (1813)
Medtech (1821)
Mergers & acquisitions (2241)
Metabolic disorders (97)
Multiple sclerosis (6)
NASH (2)
Neurodegenerative disease (24)
Neuropsychiatric disorders (7)
Neuroscience (273)
NextGen: Class of 2026 (643)
Non-profit (236)
Obesity (43)
Opinion (2)
Ovarian cancer (14)
Pain (25)
Pancreatic cancer (35)
Parkinson's disease (29)
Partnered (1)
Patents (61)
Patient recruitment (42)
Peanut (2)
People (3521)
Pharmaceutical (3)
Pharmacy benefit managers (1)
Phase 1 (1530)
Phase 2 (2306)
Phase 3 (1612)
Pipeline (946)
Policy (5)
Postmarket research (99)
Preclinical (656)
Press Release (1)
Prostate cancer (23)
Psychedelics (1)
Radiopharmaceuticals (26)
Rare diseases (50)
Real estate (252)
Recruiting (2)
Regulatory (1864)
Reports (4)
Research institute (121)
Resumes & cover letters (8)
RSV (7)
Schizophrenia (23)
Series A (16)
Series B (16)
Service/supplier (1)
Sickle cell disease (8)
Spinal muscular atrophy (3)
Sponsored (1)
Startups (101)
Supply chain (8)
Vaccines (48)
Weight loss (17)
Women's health (6)
Date
Today (19)
Last 7 days (58)
Last 30 days (229)
Last 365 days (3942)
2026 (356)
2025 (3958)
2024 (4497)
2023 (5130)
2022 (5003)
2021 (5400)
2020 (5400)
2019 (7526)
2018 (2387)
2017 (2500)
2016 (1836)
2015 (2427)
2014 (1586)
2013 (1102)
2012 (1298)
2011 (1471)
2010 (1380)
Location
Africa (19)
Alabama (7)
Arizona (39)
Asia (3108)
Australia (565)
California (1662)
Canada (397)
China (60)
Colorado (114)
Connecticut (121)
Delaware (64)
Europe (5829)
Florida (367)
Georgia (41)
Idaho (6)
Illinois (94)
India (6)
Indiana (73)
Iowa (10)
Japan (33)
Kansas (56)
Kentucky (2)
Louisiana (5)
Maine (5)
Maryland (186)
Massachusetts (925)
Michigan (46)
Minnesota (75)
Missouri (10)
Montana (2)
Nebraska (2)
Nevada (13)
New Hampshire (10)
New Jersey (414)
New York (395)
North Carolina (100)
North Dakota (1)
Northern California (937)
Ohio (62)
Pennsylvania (333)
South America (70)
South Carolina (3)
Southern California (613)
Tennessee (13)
Texas (262)
United States (5603)
Utah (44)
Virginia (42)
Washington D.C. (4)
Washington State (143)
Wisconsin (2)
Wyoming (1)
60,331 Results for "193".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
March 27, 2025
·
5 min read
Drug Development
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
May 8, 2024
·
6 min read
Press Releases
neurocare group AG Receives EUR 19.3 Million Investment From Impact Expansion and TVM Capital Healthcare
February 5, 2025
·
3 min read
BioCapital
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Acumen Pharmaceuticals, Inc. will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver on April 16, 2024.
April 16, 2024
·
8 min read
Press Releases
Multiple System Atrophy Market Size to Reach USD 193.7 Million by 2035, Impelled by Advancements in Early Detection
February 4, 2025
·
11 min read
Press Releases
[Latest] Global Alzheimer’s Drug Market Size/Share Worth USD 19.3 Billion by 2034 at a 13.03% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
June 23, 2025
·
24 min read
BioCapital
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that the Company will present data from its Phase 1 INTERCEPT-AD study evaluating sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) Annual Meeting in Denver, Colo., and online on Tuesday, April 16.
March 21, 2024
·
5 min read
Drug Development
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that results from its previously disclosed Phase 1a/1b clinical trial of zelnecirnon (formerly RPT193) were published in Allergy.
November 27, 2023
·
10 min read
Drug Development
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
Acumen Pharmaceuticals, Inc. today presented cerebrospinal fluid (CSF) biomarker data from the sabirnetug (ACU193) Phase 1 INTERCEPT-AD trial in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Lisbon, Portugal, and online.
March 8, 2024
·
8 min read
1 of 6,034
Next
